Want to see PFE full AI Analyst Report?
PFE Stock Chart & Stats
$27.56
-$0.40(-1.47%)
At close: 4:00 PM EST
$27.56
-$0.40(-1.47%)
Day’s Range― - ―
52-Week Range$23.11 - $28.75
Previous CloseN/A
Volume12.20M
Average Volume (3M)37.45M
Market Cap
$138.44B
Enterprise Value$210.48B
Total Cash (Recent Filing)$13.07B
Total Debt (Recent Filing)$64.45B
Price to Earnings (P/E)18.6
Beta0.41
Next Earnings
Aug 04, 2026EPS Estimate
0.68Next Dividend Ex-DateN/A
Dividend Yield6.65%
Share Statistics
EPS (TTM)1.31
Shares Outstanding5,699,444,300
10 Day Avg. Volume44,110,695
30 Day Avg. Volume37,449,309
Financial Highlights & Ratios
PEG Ratio-4.33
Price to Book (P/B)1.64
Price to Sales (P/S)2.26
P/FCF Ratio15.59
Enterprise Value/Market Cap1.52
Enterprise Value/Revenue3.32
Enterprise Value/Gross Profit4.79
Enterprise Value/Ebitda12.57
Forecast
1Y Price Target
$28.83Price Target Upside4.62% Upside
Rating ConsensusHold
Number of Analyst Covering22
EPS Forecast (FY)2.96
Revenue Forecast (FY)$61.72B
Bulls Say, Bears Say
Bulls Say
Late-stage R&D SuccessMultiple positive Phase III readouts materially de‑risk the pipeline, increasing probability of new approvals and label expansions. Over the medium term this supports durable revenue potential, offsets LOE, and strengthens Pfizer’s long‑term product mix and commercial optionality.
Launches & Acquired Product MomentumStrong growth from recently launched and acquired products demonstrates sustainable commercial execution beyond COVID-era sales. High single-digit launches diversify revenue, improve resilience to LOE, and signal effective integration and go‑to‑market capability that sustains midterm topline.
Margin Recovery & Cost ProgramMeaningful margin recovery and a quantified $7.2B savings program enhance structural profitability. Sustained manufacturing optimization and productivity gains raise long‑run cash generation capacity, underpinning reinvestment in R&D, dividend support, and strategic BD capacity.
Bears Say
Elevated LeverageHigher leverage reduces balance sheet flexibility and increases financing risk over the medium term. With debt elevated versus pre‑2023 levels, Pfizer has less capacity for large opportunistic M&A or accelerated buybacks without improving cash conversion or reducing net debt, constraining capital allocation optionality.
Weak Cash ConversionEarnings are not converting to cash as efficiently as historically, limiting internally generated funding for R&D, acquisitions, and shareholder returns. Persistent cash conversion gaps make Pfizer more reliant on divestitures or external financing to finance pipeline investments and absorb LOE impacts.
Multi-year LOE & COVID SeasonalityMaterial loss‑of‑exclusivity over multiple years is a structural headwind to revenues. Combined with seasonal COVID vaccine demand and muted Paxlovid utilization, this raises the bar for pipeline and BD success to replace foregone sales and sustain long‑term growth and margin targets.
Pfizer News
PFE FAQ
What was Pfizer Inc’s price range in the past 12 months?
Pfizer Inc lowest stock price was $23.11 and its highest was $28.75 in the past 12 months.
What is Pfizer Inc’s market cap?
Pfizer Inc’s market cap is $138.44B.
When is Pfizer Inc’s upcoming earnings report date?
Pfizer Inc’s upcoming earnings report date is Aug 04, 2026 which is in 34 days.
How were Pfizer Inc’s earnings last quarter?
Pfizer Inc released its earnings results on May 05, 2026. The company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.722 by $0.028.
Is Pfizer Inc overvalued?
According to Wall Street analysts Pfizer Inc’s price is currently Undervalued.
Does Pfizer Inc pay dividends?
Pfizer Inc pays a Quarterly dividend of $0.43 which represents an annual dividend yield of 6.65%. See more information on Pfizer Inc dividends here
What is Pfizer Inc’s EPS estimate?
Pfizer Inc’s EPS estimate is 0.68.
How many shares outstanding does Pfizer Inc have?
Pfizer Inc has 5,699,444,300 shares outstanding.
What happened to Pfizer Inc’s price movement after its last earnings report?
Pfizer Inc reported an EPS of $0.75 in its last earnings report, beating expectations of $0.722. Following the earnings report the stock price went up 0.572%.
Which hedge fund is a major shareholder of Pfizer Inc?
Currently, no hedge funds are holding shares in PFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pfizer Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$28.83 (4.62% Upside)
$28.83 (4.62% Upside)
Blogger Sentiment
Bullish
PFE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 53.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $51.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Very Bullish
Bullish news 89%
Bearish news 11%
Bearish news 11%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.78%
12-Months-Change
Fundamentals
Return on Equity
8.37%
Trailing 12-Months
Asset Growth
-0.20%
Trailing 12-Months
Company Description
Pfizer Inc
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
PFE Company Deck
PFE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational execution: a revenue and EPS beat, healthy underlying growth ex-COVID (~7%), substantial momentum from launched and acquired products (22% operational growth, $3.1B in Q1), multiple positive clinical readouts and meaningful strategic wins (Vyndamax settlement, favorable Belgian court ruling). Management balanced near-term challenges — LOE dynamics, COVID seasonality, higher accrued royalties and increased R&D spend — with clear actions to drive long-term growth (pipeline advancement, vaccine programs, manufacturing and cost-savings targets, BD capacity). Overall, positives around commercial performance, pipeline progress and legal/cash-flow clarity meaningfully outweigh the manageable near-term headwinds.View all PFE earnings summariesPFE Revenue Breakdown
97.79% Biopharma
0.00% PC1
0.00% Pfizer Ignite
2.21% Other business activities
PFE Stock 12 Month Forecast
Average Price Target
$28.83
▲(4.62% Upside)
Technical Analysis
Ownership Overview
0.02% Insiders
15.51% Mutual Funds
12.86% Other Institutional Investors
48.37% Public Companies and Individual Investors